Co-Diagnostics, Inc. (Co-Dx)
Co-Dx is dedicated to improving global health and preventing the spread of infectious disease by making high-quality PCR diagnostics accessible to everyone. More accurate testing means better treatments for infectious disease and higher quality of life. Co-Dx empowers patients and physicians to make informed, timely healthcare decisions, either at the point of care, at home, or in a laboratory setting, because we believe everyone deserves “the Power to Know.”
Press Releases
-
On April 12, 2024, Co-Dx announced that it held the ribbon cutting event for its new manufacturing facility in the City of South Salt Lake. The facility has been designed to manufacture the Co-Dx Pro™ instrument and test cups for the new platform, as well as the Company's patented Co-Primers® chemistry that underpins the Company's PCR diagnostic tests. Ribbon-cutting included support from Mayor Wood of South Salt Lake and other dignitaries.
-
On June 14, 2024, Co-Dx announced that it has completed its first U.S. Food and Drug Administration (FDA) application for 510(k) clearance for the Co-Dx™ PCR Pro™ instrument, and the Co-Dx PCR COVID-19 Test for over-the-counter (OTC) use. The Company expects that the application for OTC clearance will shortly be followed by pursuit of POC clearance, with other tests in the pipeline to meet the needs of a global market. The Co-Dx PCR platform has been designed to help close the access gap for infectious disease diagnosis by facilitating the widespread decentralization of gold-standard PCR diagnostics, which have historically only been found in high-complexity clinical laboratories. It consists of a compact and robust real-time PCR instrument operated at point-of-care or in at-home settings via an intuitive smartphone interface, with test cups powered by patented Co-Dx Co-Primers® technology.